Analysis: Buprenorphine and methadone should be available in corrections

Abstract

An analysis based on a simulation model suggests that making all three medications for opioid use disorder (MOUD) available to incarcerated individuals pays off in reduced overdose deaths and is more effective and cost‐effective than many correctional systems' preferred strategy of making only extended‐release naltrexone available in prison and jail settings.